Methylenedioxymethamphetamine (MDMA, 'Ecstasy')

Pediatric Emergency Care

Volumn 16, Issue 5, 2000, Pages 377-380

  Shannon, Michael ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Ecstasy; Methylenedioxymethamphetamine; Toxicology reviews

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACTIVATED CARBON; ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CENTRAL STIMULANT AGENT; DIAZEPAM; DOPAMINE RECEPTOR; HALOPERIDOL; INFUSION FLUID; MESCALINE; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NITROPRUSSIDE SODIUM; PARACETAMOL; SEDATIVE AGENT; SEROTONIN RECEPTOR; SODIUM CARBONATE;

ADULT; ALKALINIZATION; ANOREXIA; ARTICLE; CASE REPORT; DEPRESSION; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG DETOXIFICATION; DRUG INTOXICATION; DRUG OVERDOSE; EMERGENCY TREATMENT; HUMAN; HYPONATREMIA; LIVER TOXICITY; MALE; NAUSEA; NEUROLOGIC DISEASE; PSYCHOSIS; STRUCTURE ACTIVITY RELATION; SUICIDAL BEHAVIOR; TOXICITY TESTING; TREMOR; URINE PH;

ADULT; DIAGNOSIS, DIFFERENTIAL; DISSEMINATED INTRAVASCULAR COAGULATION; EMERGENCY TREATMENT; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OLIGURIA; RENAL DIALYSIS; SEIZURES;

EID: 0033789082     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006565-200010000-00022     Document Type: Article

References (36)

1. Two very different fatal cases associated with the use of methylenedioxyethylamphetamine (MDEA): Eve as deadly as Adam
2. Legal limbo for ecstasy
3. Controls over the manufacture of MDMA
4. Designer drugs
5. 'Designer drugs': A current perspective
6. Altered serotonin innervation patterns in the forebrain of monkeys treated with 3,4-methylenedioxymethamphetamine seven years previously: Factors influencing abnormal recovery
7. Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') on an undergraduate campus
8. MDMA (Ecstasy) and the rave: A review
9. The background and chemistry of MDMA
10. A growing industry and menace: Makeshift laboratory's designer drugs
11. Amphetamines
12. 'Designer drugs' - A problem in clinical toxicology
13. Differences between the mechanism of action of MDMA, MBDB, and the Classic hallucinogens, identification of a new therapeutic class: Entactogens
14. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists
15. Subjective reports on the effects of MDMA in a clinical setting
16. The biology of human information processing
17. MDMA - Nonmedical use and intoxication
18. Death by 'Ecstasy': The serotonin syndrome?
19. 'Eve' and 'Ecstasy' - A report of five deaths associated with the use of MDEA and MDMA
20. The psychological and physiological effects of MDMA on normal volunteers
21. MDMA - The dark side of ecstasy
22. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA: 'Ecstasy')
23. Urinary retention with misuse of 'Ecstasy'
24. MDMA and human sexual function
25. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('Ecstasy')
26. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy')
27. 3,4-Methylenedioxymethamphetamine (MDMA or 'Ecstasy') and associated hypoglycemia
28. Accidental ingestion of 'Ecstasy'(3,4-Methylenedioxymethamphetamine)
29. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use
30. A case of MAO inhibitor/MDMA interaction: Agony after ecstasy
31. 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates
32. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine
33. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3h]paroxetine-labeled serotonin uptake sites
34. New data intensify the agony over Ecstasy
35. Complications of 'Ecstasy' misuse